Impfen bei Immundefizienz

Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen. (IV) Impfen bei Autoimmunkrankheiten, bei anderen chronisch-entzündlichen Erkrankungen und unter immunmodulatorischer Therapie

Literatur

  1. 1.

    Ständige Impfkommission (2018) Empfehlungen der Ständige Impfkommission (STIKO) am Robert Koch-Institut. Epid Bull 34:335–382

    Google Scholar 

  2. 2.

    Aga A-B, Lie E, Uhlig T et al (2015) Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000–2010. Ann Rheum Dis 74:381–388

    Article  CAS  PubMed  Google Scholar 

  3. 3.

    Listing J, Kekow J, Manger B et al (2015) Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab. Ann Rheum Dis 74:415–421

    Article  CAS  PubMed  Google Scholar 

  4. 4.

    Lacaille D, Avina-Zubieta JA, Sayre EC, Abrahamowicz M (2017) Improvement in 5-year mortality in incident rheumatoid arthritis compared with the general population—closing the mortality gap. Ann Rheum Dis 76:1057–1063

    Article  PubMed  Google Scholar 

  5. 5.

    Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE (2002) Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 46:2287–2293

    Article  PubMed  Google Scholar 

  6. 6.

    McKinnon JE, Maksimowicz-McKinnon K (2016) Autoimmune disease and vaccination: impact on infectious disease prevention and a look at future applications. Transl Res 167:46–60

    Article  CAS  PubMed  Google Scholar 

  7. 7.

    Atzeni F, Batticciotto A, Masala IF, Talotta R, Benucci M, Sarzi-Puttini P (2016) Infections and biological therapy in patients with rheumatic diseases. Isr Med Assoc Journal: Imaj 18:164–167

    PubMed  Google Scholar 

  8. 8.

    Horneff G (2015) Biologic-associated infections in pediatric rheumatology. Curr Rheumatol Rep 17:66

    Article  CAS  PubMed  Google Scholar 

  9. 9.

    Lahiri M, Dixon W (2015) Risk of infection with biologic antirheumatic therapies in patients with rheumatoid arthritis. Best Pract Res Clin Rheumatol 29:290–305

    Article  PubMed  Google Scholar 

  10. 10.

    Shah ED, Farida JP, Siegel CA, Chong K, Melmed GY (2017) Risk for Overall Infection with Anti-TNF and Anti-integrin Agents Used in IBD: A Systematic Review and Meta-analysis. Inflamm Bowel Dis 23:570–577

    Article  PubMed  Google Scholar 

  11. 11.

    Winthrop KL, Mariette X, Silva JT et al (2018) ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect 24(Suppl 2):S21–s40

    Article  CAS  PubMed  Google Scholar 

  12. 12.

    van Assen S, Agmon-Levin N, Elkayam O et al (2011) EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 70:414–422

    Article  CAS  PubMed  Google Scholar 

  13. 13.

    Lopez A, Mariette X, Bachelez H et al (2017) Vaccination recommendations for the adult immunosuppressed patient: A systematic review and comprehensive field synopsis. J Autoimmun 80:10–27

    Article  PubMed  Google Scholar 

  14. 14.

    Oikonen M, Laaksonen M, Aalto V et al (2011) Temporal relationship between environmental influenza A and Epstein-Barr viral infections and high multiple sclerosis relapse occurrence. Mult Scler 17:672–680

    Article  PubMed  Google Scholar 

  15. 15.

    De Keyser J, Zwanikken C, Boon M (1998) Effects of influenza vaccination and influenza illness on exacerbations in multiple sclerosis. J Neurol Sci 159:51–53

    Article  PubMed  Google Scholar 

  16. 16.

    Bakare N, Menschik D, Tiernan R, Hua W, Martin D (2010) Severe combined immunodeficiency (SCID) and rotavirus vaccination: reports to the Vaccine Adverse Events Reporting System (VAERS). Vaccine 28:6609–6612

    Article  PubMed  Google Scholar 

  17. 17.

    Morillo-Gutierrez B, Worth A, Valappil M, Gaspar HB, Gennery AR (2015) Chronic Infection with Rotavirus Vaccine Strains in UK Children with Severe Combined Immunodeficiency. Pediatr Infect Dis J 34:1040–1041

    Article  PubMed  Google Scholar 

  18. 18.

    Neven B, Perot P, Bruneau J et al (2017) Cutaneous and Visceral Chronic Granulomatous Disease Triggered by a Rubella Virus Vaccine Strain in Children With Primary Immunodeficiencies. Clin Infect Dis 64:83–86

    Article  PubMed  Google Scholar 

  19. 19.

    Perelygina L, Plotkin S, Russo P et al (2016) Rubella persistence in epidermal keratinocytes and granuloma M2 macrophages in patients with primary immunodeficiencies. J Allergy Clin Immunol 138:1436–1439

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. 20.

    Loubet P, Kerneis S, Groh M et al (2015) Attitude, knowledge and factors associated with influenza and pneumococcal vaccine uptake in a large cohort of patients with secondary immune deficiency. Vaccine 33:3703–3708

    Article  PubMed  Google Scholar 

  21. 21.

    Wasan SK, Calderwood AH, Long MD, Kappelman MD, Sandler RS, Farraye FA (2014) Immunization rates and vaccine beliefs among patients with inflammatory bowel disease: an opportunity for improvement. Inflamm Bowel Dis 20:246–250

    Article  PubMed  PubMed Central  Google Scholar 

  22. 22.

    Hmamouchi I, Winthrop K, Launay O, Dougados M (2015) Low rate of influenza and pneumococcal vaccine coverage in rheumatoid arthritis: data from the international COMORA cohort. Vaccine 33:1446–1452

    Article  PubMed  Google Scholar 

  23. 23.

    Niehues T, Bogdan C, Hecht J, Mertens T, Wiese-Posselt M, Zepp F (2017) Impfen bei Immundefizienz: Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen (I) Grundlagenpapier. Bundesgesundheitsblatt 60:674–684

    Article  Google Scholar 

  24. 24.

    van Assen S, Elkayam O, Agmon-Levin N et al (2011) Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases. Autoimmun Rev 10:341–352

    Article  PubMed  Google Scholar 

  25. 25.

    Morel J, Czitrom SG, Mallick A, Sellam J, Sibilia J (2016) Vaccinations in adults with chronic inflammatory joint disease: Immunization schedule and recommendations for patients taking synthetic or biological disease-modifying antirheumatic drugs. Joint Bone Spine 83:135–141

    Article  CAS  PubMed  Google Scholar 

  26. 26.

    Confavreux C, Suissa S, Saddier P, Bourdes V, Vukusic S (2001) Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. N Engl J Med 344:319–326

    Article  CAS  PubMed  Google Scholar 

  27. 27.

    Holvast A, Huckriede A, Wilschut J et al (2006) Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. Ann Rheum Dis 65:913–918

    Article  CAS  PubMed  Google Scholar 

  28. 28.

    Farez MF, Correale J (2011) Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis. Arch Neurol 68:1267–1271

    Article  PubMed  Google Scholar 

  29. 29.

    Pool V, Gordon DM, Decker M (2012) Methodological issues with the risk of relapse study in patients with multiple sclerosis after yellow fever vaccination. Arch Neurol 69:144

    Article  PubMed  Google Scholar 

  30. 30.

    Sokka T, Abelson B, Pincus T (2008) Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol 26:S35–61

    CAS  PubMed  Google Scholar 

  31. 31.

    Smitten AL, Choi HK, Hochberg MC et al (2007) The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum 57:1431–1438

    Article  PubMed  Google Scholar 

  32. 32.

    Beukelman T, Xie F, Chen L et al (2012) Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 64:2773–2780

    Article  PubMed  PubMed Central  Google Scholar 

  33. 33.

    Bongu A, Chang E, Ramsey-Goldman R (2002) Can morbidity and mortality of SLE be improved? Best Pract Res Clin Rheumatol 16:313–332

    Article  PubMed  Google Scholar 

  34. 34.

    Al-Rayes H, Al-Swailem R, Arfin M, Sobki S, Rizvi S, Tariq M (2007) Systemic lupus erythematosus and infections: a retrospective study in Saudis. Lupus 16:755–763

    Article  CAS  PubMed  Google Scholar 

  35. 35.

    Gatto M, Agmon-Levin N, Soriano A et al (2013) Human papillomavirus vaccine and systemic lupus erythematosus. Clin Rheumatol 32:1301–1307

    Article  PubMed  Google Scholar 

  36. 36.

    Juarez M, Misischia R, Alarcon GS (2003) Infections in systemic connective tissue diseases: systemic lupus erythematosus, scleroderma, and polymyositis/dermatomyositis. Rheum Dis Clin North Am 29:163–184

    Article  PubMed  Google Scholar 

  37. 37.

    Denton CP, Khanna D (2017) Systemic sclerosis. Lancet 390(10103):1685-1699

    Article  PubMed  Google Scholar 

  38. 38.

    Phillip R, Luqmani R (2008) Mortality in systemic vasculitis: a systematic review. Clin Exp Rheumatol 26:S94–104

    CAS  PubMed  Google Scholar 

  39. 39.

    Reinhold-Keller E, Moosig F (2011) Development of morbidity and mortality in ANCA-associated vasculitis. Z Rheumatol 70:486–492

    Article  CAS  PubMed  Google Scholar 

  40. 40.

    Tegtmeyer D, Seidl M, Gerner P, Baumann U, Klemann C (2017) Inflammatory bowel disease caused by primary immunodeficiencies-Clinical presentations, review of literature, and proposal of a rational diagnostic algorithm. Pediatr Allergy Immunol 28:412–429

    Article  PubMed  Google Scholar 

  41. 41.

    Wasan SK, Baker SE, Skolnik PR, Farraye FA (2010) A practical guide to vaccinating the inflammatory bowel disease patient. Am J Gastroenterol 105:1231–1238

    Article  PubMed  Google Scholar 

  42. 42.

    Krankheitsbezogenes Kompetenznetz Multiple Sklerose eV (2016) Qualitätshandbuch Multiple Sklerose. Empfehlungen zur Therapie der MS für Ärzte. https://www.kompetenznetz-multiplesklerose.de/fachinformationen/qualitaetshandbuch/ . Zugegriffen: 04. März 2019

  43. 43.

    Mailand MT, Frederiksen JL (2017) Vaccines and multiple sclerosis: a systematic review. J Neurol 264:1035–1050

    Article  CAS  PubMed  Google Scholar 

  44. 44.

    Miller AE, Morgante LA, Buchwald LY et al (1997) A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis. Baillieres Clin Neurol 48:312–314

    CAS  Google Scholar 

  45. 45.

    Ascherio A, Zhang SM, Hernan MA et al (2001) Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med 344:327–332

    Article  CAS  PubMed  Google Scholar 

  46. 46.

    Mouchet J, Salvo F, Raschi E et al (2018) Hepatitis B vaccination and the putative risk of central demyelinating diseases—A systematic review and meta-analysis. Vaccine 36:1548–1555

    Article  PubMed  Google Scholar 

  47. 47.

    Ehl S, Bogdan C, Niehues T et al (2018) Impfen bei Immundefizienz Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen (II) Impfen bei 1. Primären Immundefekterkrankungen und 2. HIV-Infektion. Bundesgesundheitsblatt 61:1034–1051

    Article  Google Scholar 

  48. 48.

    Migita K, Akeda Y, Akazawa M et al (2015) Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus. Arthritis Res Ther 17:149

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. 49.

    Neven BPP, Bruneau J, Pasquet M, Ramirez M, Diana JS et al (2017) Cutaneous and Visceral Chronic Granulomatous Disease Triggered by a Rubella Virus Vaccine Strain in Children With Primary Immunodeficiencies. Clin Infect Dis 64:83–86

    Article  PubMed  Google Scholar 

  50. 50.

    Zhang J, Xie F, Delzell E et al (2012) Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA 308:43–49

    CAS  PubMed  PubMed Central  Google Scholar 

  51. 51.

    Azevedo LS, Lasmar EP, Contieri FL et al (2012) Yellow fever vaccination in organ transplanted patients: is it safe? A multicenter study. Transpl Infect Dis 14:237–241

    Article  CAS  PubMed  Google Scholar 

  52. 52.

    Oliveira AC, Mota LM, Santos-Neto LL, Simoes M, Martins-Filho OA, Tauil PL (2015) Seroconversion in patients with rheumatic diseases treated with immunomodulators or immunosuppressants, who were inadvertently revaccinated against yellow fever. Arthritis Rheumatol 67:582–583

    Article  PubMed  Google Scholar 

  53. 53.

    Williamson EM, Chahin S, Berger JR (2016) Vaccines in Multiple Sclerosis. Curr Neurol Neurosci Rep 16:36

    Article  CAS  PubMed  Google Scholar 

  54. 54.

    Wiedermann U, Sitte H, Burgmann H et al (2016) Impfungen bei Immundefekten/ Immunsuppression – Expertenstatus und Empfehlungen. Klin Wochenschr 128(4):337–376

  55. 55.

    Buehler S, Eperon G, Ribi C et al (2015) Vaccination recommendations for adult patients with autoimmune inflammatory rheumatic diseases. Swiss Med Wkly 145:w14159

    PubMed  Google Scholar 

  56. 56.

    Rubin LG, Levin MJ, Ljungman P et al (2014) 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 58:309–318

    Article  PubMed  Google Scholar 

  57. 57.

    Advisory Committee on Immunization Practices A (2011) General Recommendations on Immunization Recommendations of the Advisory Committee on Immunization Practices (ACIP), Recommendations and Reports / Vol. 60 / No. 2 January 28, 2011.

  58. 58.

    Public Health Agency of Canada (2018) Canadian Immunization Guide: Part 3—Vaccination of Specific Populations. https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-8-immunization-immunocompromised-persons.html#a25 ;. Zugegriffen: 17. Juli 2018

    Google Scholar 

  59. 59.

    Elkayam O (2018) on behalf of EULAR task force. Update of EULAR recommendations for vaccination of patients with autoimmune inflammatory rheumatic diseases. EULAR Kongress-Abstract, Rheumatology, Tel Aviv Medical Center, Tel Aviv, Israel

  60. 60.

    Pileggi GS, de Souza CB, Ferriani VP (2010) Safety and immunogenicity of varicella vaccine in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids. Arthritis Care Res (hoboken) 62:1034–1039

    Article  CAS  Google Scholar 

  61. 61.

    Heijstek MWKS, Armbrust W et al (2013) Effects of the Live Attenuated Measles-Mumps-Rubella Booster Vaccination on Disease Activity in Patients With Juvenile Idiopathic Arthritis A Randomized Trial. JAMA 309:2449–2456

    Article  CAS  PubMed  Google Scholar 

  62. 62.

    Heijstek MW, Ott de Bruin LM, Bijl M et al (2011) EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis 70:1704–1712

    Article  CAS  PubMed  Google Scholar 

  63. 63.

    Rubin MJL, Ljungman E, Davies EG, Avery R, Tomblyn M, Bousvaros A, Shireesha D, Sung L, Keyserling H, Insoo K, Lorry G (2013) IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host. Clin Infect Dis 58:e44–e100

    Article  PubMed  Google Scholar 

  64. 64.

    Ständige Impfkommission (2018) AG Influenza der Ständigen Impfkommission (STIKO): Wissenschaftliche Begründung für die Empfehlung des quadrivalenten saisonalen Influenzaimpfstoffs. Epidemiol Bull 2:19–28

    Google Scholar 

  65. 65.

    Park JK, Lee MA, Lee EY et al (2017) Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis 76:1559–1565

    Article  CAS  PubMed  Google Scholar 

  66. 66.

    Libbey JE, Fujinami RS (2010) Potential triggers of MS. Results Probl Cell Differ 51:21–42

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. 67.

    Ständige Impfkommission (2016) Wissenschaftliche Begründung für die Aktualisierung der Empfehlungen zur Indikationsimpfung gegen Pneumokokken für Risikogruppen. Epidemiol Bull. https://doi.org/10.17886/EpiBull-2016-055.1

    Article  Google Scholar 

  68. 68.

    Marra F, Lo E, Kalashnikov V, Richardson K (2016) Risk of Herpes Zoster in Individuals on Biologics, Disease-Modifying Antirheumatic Drugs, and/or Corticosteroids for Autoimmune Diseases: A Systematic Review and Meta-Analysis. Open Forum Infect Dis 3:ofw205

    Article  PubMed  PubMed Central  Google Scholar 

  69. 69.

    Yun H, Yang S, Chen L et al (2016) Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination. Arthritis Rheumatol 68:2328–2337

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. 70.

    Tran CT, Ducancelle A, Masson C, Lunel-Fabiani F (2017) Herpes zoster: Risk and prevention during immunomodulating therapy. Joint Bone Spine 84:21–27

    Article  PubMed  Google Scholar 

  71. 71.

    Curtis JR, Xie F, Yun H, Bernatsky S, Winthrop KL (2016) Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis 75:1843–1847

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. 72.

    Europäische Arzneimittel-Agentur, (EMA) (2018) Summary of product characteristics Shingrix(R).

  73. 73.

    Ständige Impfkommission (2018) Wissenschaftliche Begründung zur Empfehlung einer Impfung mit dem Herpes zoster-subunit-Totimpfstoff. Epid Bull. https://doi.org/10.17886/EpiBull-2017-059.2

    Article  Google Scholar 

  74. 74.

    Berkowitz EM, Moyle G, Stellbrink HJ et al (2015) Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study. J Infect Dis 211:1279–1287

    Article  CAS  PubMed  Google Scholar 

  75. 75.

    Stadtmauer EA, Sullivan KM, Marty FM et al (2014) A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. Blood 124:2921–2929

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. 76.

    Mok CC, Ho LY, Fong LS, To CH (2013) Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis 72:659–664

    Article  CAS  PubMed  Google Scholar 

  77. 77.

    MacIntyre CR, Shaw P, Mackie FE et al (2016) Immunogenicity and persistence of immunity of a quadrivalent Human Papillomavirus (HPV) vaccine in immunocompromised children. Vaccine 34:4343–4350

    Article  CAS  PubMed  Google Scholar 

  78. 78.

    Hertzell KB, Pauksens K, Rombo L, Knight A, Vene S, Askling HH (2016) Tick-borne encephalitis (TBE) vaccine to medically immunosuppressed patients with rheumatoid arthritis: A prospective, open-label, multi-centre study. Vaccine 34:650–655

    Article  CAS  PubMed  Google Scholar 

  79. 79.

    Borte S, Liebert UG, Borte M, Sack U (2009) Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept. Rheumatol (oxford) 48:144–148

    Article  CAS  Google Scholar 

  80. 80.

    Heijstek MW, Kamphuis S, Armbrust W et al (2013) Effects of the live attenuated measles-mumps-rubella booster vaccination on disease activity in patients with juvenile idiopathic arthritis: a randomized trial. JAMA 309:2449–2456

    Article  CAS  PubMed  Google Scholar 

  81. 81.

    Ständige Impfkommission (2017) Stellungnahme der Ständigen Impfkommission (STIKO) am RKI: Fachliche Anwendungshinweise zur Masern-Postexpositionsprophylaxe bei Risikopersonen. Epidemiol Bull 2:17–25. https://doi.org/10.17886/EpiBull-2017-002

    Article  Google Scholar 

  82. 82.

    Diaz PS, Au D, Smith S et al (1991) Lack of transmission of the live attenuated varicella vaccine virus to immunocompromised children after immunization of their siblings. Pediatr Electron Pages 87:166–170

    CAS  Google Scholar 

  83. 83.

    Rosenfeld L, Mas Marques A, Niendorf S et al (2017) Life-threatening systemic rotavirus infection after vaccination in severe combined immunodeficiency (SCID). Pediatr Allergy Immunol 28:841–843

    Article  PubMed  Google Scholar 

  84. 84.

    Klinkenberg D, Blohm M, Hoehne M et al (2015) Risk of Rotavirus Vaccination for Children with SCID. Pediatr Infect Dis J 34:114–115

    Article  PubMed  Google Scholar 

  85. 85.

    Ling J, Koren G (2016) Challenges in vaccinating infants born to mothers taking immunoglobulin biologicals during pregnancy. Expert Rev Vaccines 15:239–256

    Article  CAS  PubMed  Google Scholar 

  86. 86.

    Julsgaard M, Christensen LA, Gibson PR et al (2016) Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection. Baillieres Clin Gastroenterol 151:110–119

    CAS  Google Scholar 

  87. 87.

    Ostensen M (2017) The use of biologics in pregnant patients with rheumatic disease. Expert Rev Clin Pharmacol 10:661–669

    Article  CAS  PubMed  Google Scholar 

  88. 88.

    Rivera L, Pena LM, Stainier I et al (2011) Horizontal transmission of a human rotavirus vaccine strain—a randomized, placebo-controlled study in twins. Vaccine 29:9508–9513

    Article  PubMed  Google Scholar 

  89. 89.

    Arvas A (2014) Vaccination in patients with immunosuppression. Turk Pediatr Ars 49:181–185

    Article  Google Scholar 

  90. 90.

    Office of the Chief Medical Officer of Health (2017) New Brunswick, Canada, Communicable Disease Control Branch. Rotavirus Vaccination Program Questions & Answers for Immunization Providers

  91. 91.

    Dekkiche S, de Valliere S, D’Acremont V, Genton B (2016) Travel-related health risks in moderately and severely immunocompromised patients: a case-control study. J Travel. https://doi.org/10.1093/jtm/taw001

    Article  PubMed  Google Scholar 

  92. 92.

    Hall V, Johnson D, Torresi J (2018) Travel and biologic therapy: travel-related infection risk, vaccine response and recommendations. J Travel Med. https://doi.org/10.1093/jtm/tay018

    Article  PubMed  Google Scholar 

  93. 93.

    Goeijenbier M, van Genderen P, Ward BJ, Wilder-Smith A, Steffen R, Osterhaus AD (2017) Travellers and influenza: risks and prevention. J Travel Med. https://doi.org/10.1093/jtm/taw078

    Article  PubMed  Google Scholar 

  94. 94.

    Mazzola G, Macaluso FS, Adamoli L, Renna S, Cascio A, Orlando A (2017) Diagnostic and vaccine strategies to prevent infections in patients with inflammatory bowel disease. J Infect 74:433–441

    Article  PubMed  Google Scholar 

  95. 95.

    Lopez-Gigosos R, Campins M, Calvo MJ et al (2013) Effectiveness of the WC/rBS oral cholera vaccine in the prevention of traveler’s diarrhea: a prospective cohort study. Hum Vaccin Immunother 9:692–698

    Article  PubMed  PubMed Central  Google Scholar 

  96. 96.

    Wyant T, Leach T, Sankoh S et al (2015) Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. Gut 64:77–83

    Article  CAS  PubMed  Google Scholar 

  97. 97.

    Staples JE, Gershman M, Fischer M (2010) Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). Mmwr Recomm Rep 59:1–27

    PubMed  Google Scholar 

  98. 98.

    Burchard GD, Caumes E, Connor BA et al (2009) Expert opinion on vaccination of travelers against Japanese encephalitis. J Travel Med 16:204–216

    Article  PubMed  Google Scholar 

  99. 99.

    Rosdahl A, Herzog C, Frösner G, Norén T, Rombo L, Askling HH (2018) An extra priming dose of hepatitis A vaccine to adult patients with rheumatoid arthritis and drug induced immunosuppression–A prospective, open-label, multi-center study. Trav med infect dis 21:43-50

  100. 100.

    Alten R, Bingham CO 3rd, Cohen SB et al (2016) Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept. Bmc Musculoskelet Disord 17:231

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. 101.

    Ribeiro AC, Laurindo IM, Guedes LK et al (2013) Abatacept and reduced immune response to pandemic 2009 influenza A/H1N1 vaccination in patients with rheumatoid arthritis. Arthritis Care Res (hoboken) 65:476–480

    Article  CAS  Google Scholar 

  102. 102.

    Tay L, Leon F, Vratsanos G, Raymond R, Corbo M (2007) Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects. Arthritis Res Ther 9:R38

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. 103.

    Kaine JL, Kivitz AJ, Birbara C, Luo AY (2007) Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol 34:272–279

    CAS  PubMed  Google Scholar 

  104. 104.

    Pratt PK Jr., David N, Weber HC et al (2018) Antibody Response to Hepatitis B Virus Vaccine is Impaired in Patients With Inflammatory Bowel Disease on Infliximab Therapy. Inflamm Bowel Dis 24:380–386

    Article  PubMed  Google Scholar 

  105. 105.

    McCarthy CL, Tuohy O, Compston DA, Kumararatne DS, Coles AJ, Jones JL (2013) Immune competence after alemtuzumab treatment of multiple sclerosis. Baillieres Clin Neurol 81:872–876

    CAS  Google Scholar 

  106. 106.

    Papp K, Reich K, Leonardi CL et al (2015) Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol 73:37–49

    Article  CAS  PubMed  Google Scholar 

  107. 107.

    Public Health England (2017) Chapter 6 Contraindications and special considerations. In: Immunisation against infectious disease

    Google Scholar 

  108. 108.

    Holvast A, van Assen S, de Haan A et al (2009) Studies of cell-mediated immune responses to influenza vaccination in systemic lupus erythematosus. Arthritis Rheum 60:2438–2447

    Article  CAS  PubMed  Google Scholar 

  109. 109.

    Battafarano DF, Battafarano NJ, Larsen L et al (1998) Antigen-specific antibody responses in lupus patients following immunization. Arthritis Rheum 41:1828–1834

    Article  CAS  PubMed  Google Scholar 

  110. 110.

    Chatham W, Chadha A, Fettiplace J et al (2017) A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus. Lupus 26(14):1483-1490. https://doi.org/10.1177/0961203317703495

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  111. 111.

    Nagel J, Saxne T, Geborek P et al (2017) Treatment with belimumab in systemic lupus erythematosus does not impair antibody response to 13-valent pneumococcal conjugate vaccine. Lupus 26:1072–1081

    Article  CAS  PubMed  Google Scholar 

  112. 112.

    Chioato A, Noseda E, Felix SD et al (2010) Influenza and meningococcal vaccinations are effective in healthy subjects treated with the interleukin-1 beta-blocking antibody canakinumab: results of an open-label, parallel group, randomized, single-center study. Clin Vaccine Immunol 17:1952–1957

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  113. 113.

    Kivitz AJ, Schechtman J, Texter M, Fichtner A, de Longueville M, Chartash EK (2014) Vaccine responses in patients with rheumatoid arthritis treated with certolizumab pegol: results from a single-blind randomized phase IV trial. J Rheumatol 41:648–657

    Article  CAS  PubMed  Google Scholar 

  114. 114.

    Heijstek MW, Ott de Bruin LM, Borrow R et al (2011) Vaccination in paediatric patients with auto-immune rheumatic diseases: a systemic literature review for the European League against Rheumatism evidence-based recommendations. Autoimmun Rev 11:112–122

    Article  CAS  PubMed  Google Scholar 

  115. 115.

    von Hehn C, Howard J, Liu S et al (2018) Immune response to vaccines is maintained in patients treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm 5:e409

    Article  Google Scholar 

  116. 116.

    Mease PJ, Ritchlin CT, Martin RW et al (2004) Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J Rheumatol 31:1356–1361

    CAS  PubMed  Google Scholar 

  117. 117.

    Aikawa NE, Franca IL, Ribeiro AC, Sallum AM, Bonfa E, Silva CA (2015) Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy. Vaccine 33:604–609

    Article  CAS  PubMed  Google Scholar 

  118. 118.

    Rakoczi E, Perge B, Vegh E et al (2016) Evaluation of the immunogenicity of the 13-valent conjugated pneumococcal vaccine in rheumatoid arthritis patients treated with etanercept. Joint Bone Spine 83:675–679

    Article  CAS  PubMed  Google Scholar 

  119. 119.

    Dell’Era L, Corona F, Daleno C, Scala A, Principi N, Esposito S (2012) Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritis. Vaccine 30:936–940

    Article  CAS  PubMed  Google Scholar 

  120. 120.

    Kappos L, Mehling M, Arroyo R et al (2015) Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis. Baillieres Clin Neurol 84:872–879

    CAS  Google Scholar 

  121. 121.

    Boulton C, Meiser K, David OJ, Schmouder R (2012) Pharmacodynamic effects of steady-state fingolimod on antibody response in healthy volunteers: a 4-week, randomized, placebo-controlled, parallel-group, multiple-dose study. J Clin Pharmacol 52:1879–1890

    Article  CAS  PubMed  Google Scholar 

  122. 122.

    Olberg HK, Eide GE, Cox RJ et al (2018) Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy. Eur J Neurol 25:527–534

    Article  CAS  PubMed  Google Scholar 

  123. 123.

    Duda PW, Schmied MC, Cook SL, Krieger JI, Hafler DA (2000) Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest 105:967–976

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  124. 124.

    Migita K, Akeda Y, Akazawa M et al (2015) Opsonic and Antibody Responses to Pneumococcal Polysaccharide in Rheumatoid Arthritis Patients Receiving Golimumab Plus Methotrexate. Medicine (Baltimore) 94:e2184

    Article  CAS  Google Scholar 

  125. 125.

    Gabay C, Bel M, Combescure C et al (2011) Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. Arthritis Rheum 63:1486–1496

    Article  CAS  PubMed  Google Scholar 

  126. 126.

    Miehsler W, Novacek G, Wenzl H et al (2010) A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. J Crohns Colitis 4:221–256

    Article  CAS  PubMed  Google Scholar 

  127. 127.

    Hagihara Y, Ohfuji S, Watanabe K et al (2014) Infliximab and/or immunomodulators inhibit immune responses to trivalent influenza vaccination in adults with inflammatory bowel disease. J Crohns Colitis 8:223–233

    Article  PubMed  Google Scholar 

  128. 128.

    deBruyn J, Fonseca K, Ghosh S et al (2016) Immunogenicity of Influenza Vaccine for Patients with Inflammatory Bowel Disease on Maintenance Infliximab Therapy: A Randomized Trial. Inflamm Bowel Dis 22:638–647

    Article  PubMed  Google Scholar 

  129. 129.

    Fiorino G, Peyrin-Biroulet L, Naccarato P et al (2012) Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis 18:1042–1047

    Article  PubMed  Google Scholar 

  130. 130.

    Andrade P, Santos-Antunes J, Rodrigues S, Lopes S, Macedo G (2015) Treatment with infliximab or azathioprine negatively impact the efficacy of hepatitis B vaccine in inflammatory bowel disease patients. J Gastroenterol Hepatol 30:1591–1595

    Article  CAS  PubMed  Google Scholar 

  131. 131.

    Visvanathan S, Keenan GF, Baker DG, Levinson AI, Wagner CL (2007) Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone. J Rheumatol 34:952–957

    CAS  PubMed  Google Scholar 

  132. 132.

    Schwid SR, Decker MD, Lopez-Bresnahan M (2005) Immune response to influenza vaccine is maintained in patients with multiple sclerosis receiving interferon beta-1a. Baillieres Clin Neurol 65:1964–1966

    CAS  Google Scholar 

  133. 133.

    Kapetanovic MC, Saxne T, Nilsson JA, Geborek P (2007) Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatol (oxford) 46:608–611

    Article  CAS  Google Scholar 

  134. 134.

    Kapetanovic MC, Saxne T, Sjoholm A, Truedsson L, Jonsson G, Geborek P (2006) Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatol (oxford) 45:106–111

    Article  CAS  Google Scholar 

  135. 135.

    Olberg HK, Cox RJ, Nostbakken JK, Aarseth JH, Vedeler CA, Myhr KM (2014) Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study. Mult Scler 20:1074–1080

    Article  CAS  PubMed  Google Scholar 

  136. 136.

    Kaufman M, Pardo G, Rossman H, Sweetser MT, Forrestal F, Duda P (2014) Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis. J Neurol Sci 341:22–27

    Article  CAS  PubMed  Google Scholar 

  137. 137.

    Vagberg M, Kumlin U, Svenningsson A (2012) Humoral immune response to influenza vaccine in natalizumab-treated MS patients. Neurol Res 34:730–733

    Article  CAS  PubMed  Google Scholar 

  138. 138.

    Oren S, Mandelboim M, Braun-Moscovici Y et al (2008) Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann Rheum Dis 67:937–941

    Article  CAS  PubMed  Google Scholar 

  139. 139.

    Crnkic Kapetanovic M, Saxne T, Jonsson G, Truedsson L, Geborek P (2013) Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis. Arthritis Res Ther 15:R171

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  140. 140.

    Bingham CO 3rd, Looney RJ, Deodhar A et al (2010) Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum 62:64–74

    Article  CAS  PubMed  Google Scholar 

  141. 141.

    Nguyen DL, Nguyen ET, Bechtold ML (2015) Effect of Immunosuppressive Therapies for the Treatment of Inflammatory Bowel Disease on Response to Routine Vaccinations: A Meta-Analysis. Dig Dis Sci 60:2446–2453

    Article  CAS  PubMed  Google Scholar 

  142. 142.

    Chioato A, Noseda E, Stevens M, Gaitatzis N, Kleinschmidt A, Picaud H (2012) Treatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label, parallel-group, randomized single-center study. Clin Vaccine Immunol 19:1597–1602

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  143. 143.

    Trollmo C, Gudmundsson S, Feltelius N, Rogberg S, Smedegard G, Klareskog L (2007) Sulphasalazine inhibits human antigen-specific immune responses in vivo. Ann Rheum Dis 66:481–485

    Article  CAS  PubMed  Google Scholar 

  144. 144.

    Zonneveld-Huijssoon E, Ronaghy A, Van Rossum MA et al (2007) Safety and efficacy of meningococcal c vaccination in juvenile idiopathic arthritis. Arthritis Rheum 56:639–646

    Article  PubMed  Google Scholar 

  145. 145.

    Bar-Or A, Freedman MS, Kremenchutzky M et al (2013) Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis. Baillieres Clin Neurol 81:552–558

    CAS  Google Scholar 

  146. 146.

    Bar-Or A, Wiendl H, Miller B et al (2015) Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens. Neurol Neuroimmunol Neuroinflamm 2:e70

    Article  PubMed  PubMed Central  Google Scholar 

  147. 147.

    Tsuru T, Terao K, Murakami M et al (2014) Immune response to influenza vaccine and pneumococcal polysaccharide vaccine under IL-6 signal inhibition therapy with tocilizumab. Mod Rheumatol 24:511–516

    Article  CAS  PubMed  Google Scholar 

  148. 148.

    Mori S, Ueki Y, Akeda Y et al (2013) Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy. Ann Rheum Dis 72:1362–1366

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  149. 149.

    Bingham CO 3rd, Rizzo W, Kivitz A, Hassanali A, Upmanyu R, Klearman M (2015) Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA). Ann Rheum Dis 74:818–822

    Article  CAS  PubMed  Google Scholar 

  150. 150.

    Winthrop KL, Wouters AG, Choy EH et al (2017) The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial. Arthritis Rheumatol 69:1969–1977

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  151. 151.

    Winthrop KL, Silverfield J, Racewicz A et al (2016) The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. Ann Rheum Dis 75:687–695

    Article  CAS  PubMed  Google Scholar 

  152. 152.

    Winthrop K, Korman N, Abramovits W et al (2017) T cell-mediated immune response to pneumococcal conjugate vaccine (PCV-13) and tetanus toxoid vaccine in patients with moderate to severe psoriasis during tofacitinib treatment. J Am Acad Dermatol 78(6):1149-1155. https://doi.org/10.1016/j.jaad.2017.09.076

    CAS  Article  Google Scholar 

  153. 153.

    Brodmerkel C, Wadman E, Langley RG et al (2013) Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use. J Drugs Dermatol 12:1122–1129

    CAS  PubMed  Google Scholar 

Download references

Danksagung

Für die kritische und konstruktive Durchsicht des Manuskripts danken wir allen in der STIKO-Arbeitsgruppe Immundefizienz mitarbeitenden Expertinnen und Experten sowie Judith Koch und Wiebe Külper aus dem Fachgebiet Impfprävention am Robert Koch Institut.

Interessenkonflikt

N. Wagner, F. Assmus, G. Arendt, E. Baum, U. Baumann, C. Bogdan, G. Burchard, D. Föll, E. Garbe, J. Hecht, U. Müller-Ladner, T. Niehues, K. Überla, S. Vygen-Bonnet, T. Weinke, M. Wiese-Posselt, M. Wojcinski und F. Zepp geben an, dass kein Interessenkonflikt besteht.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Sabine Vygen-Bonnet.

Caption Electronic Supplementary Material

Anhang

Anhang

Siehe Tab. A-2

Tab. A-2 Immunsupprimierende bzw. immunmodulierende Arzneistoffe und zu berücksichtigende Impfabstände und weitere Aspekte bei Monotherapie (Stand 20.07.2018)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Wagner, N., Assmus, F., Arendt, G. et al. Impfen bei Immundefizienz. Bundesgesundheitsbl 62, 494–515 (2019). https://doi.org/10.1007/s00103-019-02905-1

Download citation